Abstract
Purpose: Robust pharmaceutical and industrial enzymes from extremophile microorganisms are main source of enzymes with tremendous stability under harsh conditions which make them potential tools for commercial and biotechnological applications.
Methods: The genome of a Gram-positive halo-thermotolerant Bacillus sp. SL1, new isolate from Saline Lake, was investigated for the presence of genes coding for potentially pharmaceutical enzymes. We determined gene sequences for the enzymes laccase (CotA), l-asparaginase (ansA3, ansA1), glutamate-specific endopeptidase (blaSE), l-arabinose isomerase (araA2), endo-1,4-β mannosidase (gmuG), glutaminase (glsA), pectate lyase (pelA), cellulase (bglC1), aldehyde dehydrogenase (ycbD) and allantoinases (pucH) in the genome of Bacillus sp. SL1.
Results: Based on the DNA sequence alignment results, six of the studied enzymes of Bacillus sp. SL-1 showed 100% similarity at the nucleotide level to the same genes of B. licheniformis 14580 demonstrating extensive organizational relationship between these two strains. Despite high similarities between the B. licheniformis and Bacillus sp. SL-1 genomes, there are minor differences in the sequences of some enzyme. Approximately 30% of the enzyme sequences revealed more than 99% identity with some variations in nucleotides leading to amino acid substitution in protein sequences.
Conclusion: Molecular characterization of this new isolate provides useful information regarding evolutionary relationship between B. subtilis and B. licheniformis species. Since, the most industrial processes are often performed in harsh conditions, enzymes from such halo-thermotolerant bacteria may provide economically and industrially appealing biocatalysts to be used under specific physicochemical situations in medical, pharmaceutical, chemical and other industries.
Keywords: Molecular characterization, Pharmaceutical enzymes, Gene sequence, Halo-thermo tolerant Bacillus
Introduction
Production of raw materials using enzymes is a rapidly expanding technology especially in the pharmaceutical and biotechnology industries. It is an excellent tool for replacing harmful traditional chemical synthesis by environmentally-friendly bio-based processes.1-3 The chemical synthesis of compounds and pharmaceuticals has several disadvantages such as low catalytic efficiency, lack of chemo-, regio- and enantio-selectivity, and needs for specific conditions in terms of temperature, pH and pressure, just to mention a few. Also, the use of organic solvents leads to environmental issues brought about by organic waste and pollutants. The ability of enzymes to catalyze chemical reaction with high speed and specificity under mild reaction conditions has made them appropriate alternatives to conventional chemical reactions in industry4 and progressively useful in preparation of diverse products2,5 such as chiral medicines, biosensors, biofuels, detergents and textiles, pulp and paper, leather and animal feed.
The use of the therapeutic enzymes dates back around 40 years ago. The great affinity and specificity of such enzymes for binding and acting on their targets, distinguish them from all other types of drugs. Moreover enzymes can act as biocatalysts to convert several molecules to the desired products.6 These distinct characteristics have resulted in the development of many therapeutic enzymes for a variety of diseases.7
Enzyme-activation prodrug therapy is one of the promising area to overcome the limitations of chemotherapeutic agents such as insufficient drug concentrations in tumors, systemic toxicity, lack of selectivity for tumor cells and drug-resistance problems in tumor cells.8,9 The enzyme-prodrug cancer therapy is achieved by delivering the drug-activating enzyme gene or functional protein from nonhuman or human origin in to the tumor tissues accompanied with the simultaneous administration of a prodrug.10,11 Pro-drugs are nontoxic chemically modified versions of the pharmacologically active agents that can be converted to the active and cytotoxic anticancer drugs with high local concentrations in tumors.12
The synthesis of biologically active compounds through enzymatic transformation can provide an efficient way of achieving novel antimicrobial agents required to overcome the global problem of antibiotic resistance development.13
Currently, out of almost 4000 enzymes, about 200 are used commercially. The majority of the industrial enzymes are of microbial origin14 and prepared as recombinant proteins mostly in bacteria and/or yeast as the host expression system.15-17 Microbial enzymes are preferred over plant or animal sources due to their economic production costs and simplicity of the modification and optimization process. They are relatively more stable than corresponding enzymes derived from plants or animals and they provide a greater diversity of catalytic activities.18
The special features of microbial enzymes which make them potential source for commercial and industrial applications include thermotolerance, thermophilic nature, and stability over broad range of temperature and pH, and other harsh reaction conditions.1 Nature is the main source of enzyme producing microorganisms among them the great diversity of extremophiles supply the valuable enzymes with robust properties.19 Extremophile microorganisms produce enzymes with great stability under harsh conditions which are regarded as incompatible environmental properties for biological systems.15
The halo-thermotolerant Bacillus sp. SL-1 is a Gram-positive, spore-forming bacterium that was isolated from Aran-Bidgol Saline Lake in central region of Iran as introduced in previous study.20 Enzymes from halophiles tolerate such harsh environments by acquiring a large number of negatively-charged residues in their surfaces, which leads to their very low propensity for aggregation. Such a property has been taken as an advantage for these enzymes allowing them to function in non-aqueous media.21 Phylogenetic analysis based on 16S rDNA gene sequence comparisons revealed that the isolate Bacillus sp. SL-1 was closely related to Bacillus licheniformis with 97% similarity. The B. licheniformis is an important producer of exoenzymes and has been used for decades in large-scale manufacturing the industrial and pharmaceutical enzymes such as different proteases, α-amylase, penicillinase, pentosanase, β-mannanase and several pectinolytic enzymes.22,23 Based on complete genome sequence of B. licheniformis, many new genes for enzymes with potential biotechnological and pharmaceutical applications were found.23 With the recent advances in biotechnology, various enzymes have been identified and designed or purposely engineered to produce more (and most likely new) chemicals and materials from cheaper (and renewable) resources, which will consequently contribute to establishing a bio-based economy.15
The halo-thermotolerant Bacillus sp. SL-1 as a new and locally isolated extremophile can be regarded as a resource for many useful pharmaceutical enzymes on commercial scales. In this study, based on the similarity observed for Bacillus sp. SL-1 and B. licheniformis (ATCC 14580), the two strains were considered closely related and hence the coding sequence for ten pharmaceutically and industrially important enzymes including laccase, l-asparaginase, glutamate-specific endopeptidase, L-arabinose isomerase, endo-1,4-β mannosidase, glutaminase, pectate lyase, cellulose, aldehyde dehydrogenase and allantoinases were inspected in the Bacillus sp. SL-1. The gene for these enzymes were identified, amplified, sequenced and compared with corresponding gene from the genome of the other Bacillus in database leading to the first analysis of enzymatic profile from Bacillus sp. SL-1. The results were indicative of opportunity for this organism as an industrial strain.
Materials and Methods
Materials
All reagents were of analytical grade. Tryptone and NaCl were purchased from Scharlau (Barcelona, Spain). Yeast extract, agar and glycerol were from Applichem (Darmstadt, Germany). DNA extraction kit was received from Qiagen (Germany). DNA ladders and Pfu PCR PreMix master mix were obtained from Fermentas (Russia) and Bioneer (South Korea), respectively. Safe stain was purchased from Thermo Scientific (USA). Primers used in this work were supplied from Bioron (Germany) ordered via FAZA Biotech (Tehran, Iran).
Strains and culture media
Halo-thermotolerant Bacillus sp. SL-1 was isolated from Aran-Bidgol Saline Lake in central region of Iran as introduced in previous study.20 This isolate deposited in Iranian Biological Resources Center (approved by World Federation for Culture Collections: WDCM950) for availability to scientific community (IBRC-M 11052). Bacillus sp. SL-1 was cultivated overnight in enriched Luria–Bertani (LB) medium at 35 °C and 180 rpm.
Primer Design
The design of primers for laccase (CotA), l-asparaginase (ansA1, ansA3), glutamate-specific endopeptidase (blaSE), l-arabinose isomerase (araA2), endo-1,4-β mannosidase (gmuG), glutaminase (glsA), pectate lyase (pelA), cellulase (bglC1), aldehyde dehydrogenase (ycbD) and allantoinases (pucH) enzymes from Bacillus sp. SL-1 were based on the complete genome sequence of B. licheniformis (GenBank accession no. AE017333.1) and other closely related Bacillus, which permits the prediction of coding sequence for the ten selected enzymes according to the conserved regions in their sequences. Table 1 shows the list of designed primers for the enzymes.
Table 1. The primer pairs for amplification of enzyme genes from Bacillus sp.SL-1 genome. The primers designed according to the complete genome of B. licheniformis ATCC14580 .
| Locus-tag | Genes | Primers (5ʹ-3ʹ) | PCR product size (bp) |
| BLi00679 | CotA | TGGACATATGAAACTTGAAAAATTCGTTGACCGGC TGAACTCGAGTTGATGACGAACATCTGTCACTTC |
1450 |
| BLi04140 | ansA3 | GTAGCATATGAAAAAGTTACTGCTGTTGACCACC CTTGCGGCCGC TATGATGATATCGTCTGCAATCGG |
980 |
| BLi02433 | ansA1 | TCTTCATATGAATAAAAAAGTAGCTCTCATTACAACG AACAGTCGACCTAATAGCAGAATTTGTCTTTTATGCCTT |
969 |
| BLi00340 | blaSE | ATATCATATGGTTAGTAAAAAGAGTGTTAAACGAGG GCCCTCGAGTTGTGCGCTGTTTTTCCAGTTGG |
945 |
| BLi03028 | araA2 | ATGTTAACAACAGGGAAAAAAGAATT TTACTTAATCACTACATATTCCAAGTC |
1425 |
| BLi00735 | gmuG | CACACACCGTTTCTCCGGTG ACAGGCGTCAAAGAATCGCC |
1003 |
| BLi00274 | glsA | ATGAATGAAGTATTGGAAGAACGCTATGAC TACTGAGATCCCATTCACGGGCTATATG |
984 |
| BLi04129 | pelA | AGGGGTTGTCGGGTCATTGA TGGATTGATTTTGCCGACTCC |
980 |
| BLi00387 | bglC1 | GGGTGTCCCTTAACGAGCAA GCTCTTCCCCGTTTGTCTGA |
945 |
| BLi00285 | ycbD | ATGTCTGTTGCAGCTGAAAGTAAAACG TTACGGTTTGACAAATACGGTTTTCAC |
1460 |
| BLi01126 | pucH | ATCAAGTGCCAGCAACGGTA CCCTACTGCAATACTGCCTT |
860 |
Polymerase Chain Reaction (PCR)
Genomic DNA from Bacillus sp. SL-1 was extracted by QIAamp DNA kit (Qiagen, Germany) according to the supplier’s instruction. The amplification reaction mixtures were prepared to the final volume of 25 µl containing the 12 µl Pfu PCR PreMix master mix, 0.5 µl of forward and reverse primers (10 pmol/ µl), 2 µl DNA template (150 ng) and 10 µl PCR grade water. The PCR protocol adjusted for the amplification of the genes for all enzymes was performed using the following program: initial denaturation at 94 °C for 3 min, followed by 35 cycles of denaturation at 94 °C for 1 min, annealing at 56 °C for 90 s, and extension at 72 °C for 2 min with final extension at 72 °C for 10 min. PCR products were analyzed on 1% agarose gel stained with safe stain and visualized under ultraviolet transillumination (Syngene InGenius, USA).
Sequence analysis
For further information about the sequence of the amplified genes the PCR products were sent out for sequencing at Sequetech, USA. Database search for the homologous sequences was performed using BLAST program from National Center for Biotechnology Information. Sequence alignments of the gene sequences were performed using CLUSTALW.24
Enzyme sequence accession numbers
The complete nucleotide sequences for the identified enzymes from Bacillus sp. SL-1 have been submitted to GenBank with following accession numbers: laccase (KU711667), l-asparaginase (KX129701, KX681674 ), glutamate-specific endopeptidase (KX129706), l-arabinose isomerase (KX129703), endo-1,4-β mannosidase (KX129704), glutaminase (KX129699), pectate lyase (KX129700), cellulose (KX129698), aldehyde dehydrogenase (KX129705) and allantoinase (KX129702).
Results and Discussion
Identification of putative Bacillus sp. SL-1 enzymes
According to the higher similarity (97%) observed between the16S rDNA gene sequences for Bacillus sp. SL-1 and B. licheniformis (ATCC 14580), the complete genome sequence from later was used as a template for designing appropriate primers for amplifying the corresponding enzyme genes from the genome of the SL-1 strain. The B. licheniformis belongs to the B. subtilis group (group II) of the genus Bacillus together with other well-known species whose complete genome sequence has been determined.23 The genome of B. licheniformis ATCC 14580 is in the form of a circular chromosome of 4,222,336 base-pairs (bp), which was predicted to be consist of 4,208 protein-coding sequences (CDSs). Based on a broad investigation on B. licheniformis genome, at least 82 of the 4,208 genes are likely to encode secreted proteins and enzymes. In addition, there are 27 predicted extracellular proteins encoded by the B. licheniformis (ATCC 14580) genome that are not found in B. subtilis 168. Due to the saprophytic lifestyle, the B. licheniformis encodes several secreted enzymes that hydrolyze polysaccharides, proteins, lipids and other nutrients.22 Because of the biotechnological importance of this group of organisms we characterized the genes for ten industrial enzymes from the isolated halo-thermo tolerant Bacillus SL-1 and present the first analysis of data derived from the annotated sequences.
In this study selected enzyme genes were amplified from total genomic DNA of type strain SL-1 by using specific primer pairs and then the PCR products were visualized by gel electrophoresis on 1% agarose gel stained with safe stain. The gel image analysis indicated bands with sizes in the range of 860 to 1460 bp (Figure 1) that confirmed the presence of four industrially important classes of enzyme genes (EC1, EC3, EC4 and EC5) in Bacillus SL-1 genome. According to the Enzyme Commission the enzymes are divided into 6 class containing oxidoreductase (EC 1), transferase (EC 2), hydrolase (EC 3), lyase (EC 4), isomerase (EC 5) and ligase (EC 6).25 The classification of the studied enzymes of Bacillus sp. SL-1 was shown in Table 2.
Figure 1.

Gel electrophoresis results of enzyme genes from Bacillus sp. SL-1. Lane 1, l-arabinose isomerase (~1450 bp); lane 2, laccase (~1500 bp); lane 3, DNA Ladder; lane 4, glutamate-speicific endopeptidase (~950 bp); lane 5, l-asparaginase (~980 bp); lane 6, endo-1,4-β mannosidase (~1000 bp); lane 7, glutaminase (~990 bp); lane 8, pectate lyase (~980 bp); lane 9, cellulose (~950 bp); lane 10, aldehyde dehydrogenase (~1500 bp); lane 11, allantoinase (~860 bp).
Table 2. Industrial enzyme classes of Bacillus sp. SL-1 and types of reactions .
| Enzyme commission number (EC) | Class of enzymes | Industrial enzymes of Bacillus sp. SL-1 |
| EC1 | Oxidoreductases | Laccase |
| Aldehyde dehydrogenase | ||
| EC3 | Hydrolases | Cellulase |
| Allantoinases | ||
| Glutaminase | ||
| L-asparaginase | ||
| Endo-1,4-β mannosidase | ||
| Glutamate-specific endopeptidase | ||
| EC4 | Lyases | Pectate lyase |
| EC5 | Isomerases | L-arabinose isomerase |
Sequence analysis of Bacillus sp. SL-1 enzymes
Search for the homologs of the selected enzymes was performed by BLAST algorithm using the DNA sequences of the query enzymes against the nucleotide collection database. The most similar homologs for the studied enzymes were from B. licheniformis (ATCC 14580) with similarities ranging from 99 to 100% shown in Table 3. The table also contains the comparisons between the genes for the selected enzymes and the corresponding genes from B. subtilis, which is another closely related strain, albeit with less similarities (51-75%) in the case of these enzymes. Although the SL-1 isolate is considered closely related to the B. licheniformis, based on sequence similarities for the target enzymes, however, they are distinctive strains according to the 16S rDNA sequencing and some physicochemical properties described previously.20 The comparative sequence analyses for the ten selected enzymes between Bacillus sp. SL-1 and B. licheniformis ATCC14580 were performed at the protein level by CLUSTAL-W pairwise alignment using the translated protein sequences (Table 4). More details regarding individual enzymes investigated in this work presented below.
Table 3. Comparison of the corresponding gene from the genome of Bacillus sp. SL-1 with B. licheniformis ATCC14580 and B. subtilis168 .
| Genes | Alignment (Identity %) | GenBank Accession numbers | |
| B. licheniformis 14580 | B. subtilis 168 | ||
| CotA | 99.94 | 64.65 | KU711667 |
| bglC1 | 100.0 | 76.43 | KX129698 |
| glsA | 99.70 | 72.36 | KX129699 |
| pelA | 100.0 | 51.12 | KX129700 |
| pucH | 99.66 | 51.05 | KX129702 |
| ansA3 | 99.90 | 72.04 | KX129701 |
| ansA1 | 99.48 | 46.35 | KX681674 |
| araA2 | 100.0 | 57.52 | KX129703 |
| gmuG | 100.0 | 72.48 | KX129704 |
| ycbD | 100.0 | 74.23 | KX129705 |
| blaSE | 100.0 | 56.80 | KX129706 |
Table 4. Pairwise alignment of Bacillus sp. SL-1 enzymes with B. licheniformis (ATCC14580) complete genome .
| Enzymes | Protein sequence alignment | ||
| Nucleotide modification | Amino acid modification | Identity (%) | |
| Laccase ( CotA) | A948C | K316 to N | 99.94 |
| Cellulase (bglC1) | None | None | 100.0 |
| Glutaminase (glsA) | C345T | None | 99.44 |
| A435G | I145 to M | ||
| A649T | I217 to F | ||
| Pectate lyase (pelA) | None | None | 100.0 |
| Allantoinase (pucH) | G397A | D133 to N | 99.36 |
| C850A | H284 to N | ||
| C896T | S299 to L | ||
| L-asparaginase (ansA3) | T522A | None | 100.0 |
| L-asparaginase (ansA1) | A177T | None | 99.07 |
| C184G | Q62 to E | ||
| G229A | D77 to N | ||
| C462T | None | ||
| A946T | I316 to L | ||
| L-arabinose isomerase (araA2) | None | None | 100.0 |
| Endo-1,4-β mannosidase (gmuG) | None | None | 100.0 |
| Aldehyde dehydrogenase (ycbD) | None | None | 100.0 |
| Glutamate-specific endopeptidase (blaSE) | None | None | 100.0 |
Oxidoreductases (EC 1)
Oxidoreductase enzymes catalyze oxidation-reduction reactions where electrons are transferred. These electrons are usually in the form of hydride ions or hydrogen atoms. When a substrate is oxidized it acts as the hydrogen donor in the reaction and therefore the most common name used for the enzymes catalyzing this reaction is dehydrogenase. An oxidase is referred to when the oxygen atom is the electron acceptor.26
Laccases (EC 1.10.3.2), belonging to the superfamily of multicopper oxidases, catalyze the reduction of oxygen molecule into water molecule via transferring the electrons from substrates. Due to high capacity for the oxidation of wide range of phenols and polyphenols to highly reactive radicals, laccases have potential for applications in biotechnology, especially in the synthesis of new biologically active compounds and biomaterials.3,27 These radicals can undergo coupling reactions with various types of compounds, which can lead to the formation of products with new structures and properties.3 For example, laccase-catalyzed amination of dihydroxy aromatics is a new and promising method to synthesize novel antibiotics via enzymatic transformation.13 These laccase mediated reactions are low-cost reactions which are conducted under mild reaction conditions, in aqueous solvent systems, normal pressure, and room temperature.28,29 Up to now, novel cephalosporins, penicillins, and carbacephems were synthesized by amination of amino-β-lactam structures using laccases.13,28,30 Other examples of the potential application of laccases for organic synthesis include the oxidative coupling of katarantine and vindoline to produce vinblastine.31 Vinblastine is an important anti-cancer agent, extensively used in treatment of leukemia.31
The CotA genes from Bacillus sp. SL-1 and B. licheniformis ATCC14580 are almost identical (99.94%), except for a single A948C nucleotide difference, which has led to K316N substitution as indicated in Table 3. Multiple sequence alignment of laccase from Bacillus sp. SL-1 with other laccase enzymes from different Bacillus strains indicated four conserved segments containing histidine-rich copper-binding sites which are characteristic for bacterial laccases. Moreover, the CotA(SL-1) gene from Bacillus sp. SL-1 shows 64.65% identity with CotA from B. subtilis. The most important advantages of using bacterial laccases are their higher activity as well as stability at various pH and temperature compared to the fungal laccase. Moreover, the expression level of laccase is anticipated to be higher in bacteria than other microorganisms, which may provide added economic values for its use. Besides, the industrial processes are often conducted in harsh conditions such as extreme pH, temperature, or ionic strength and therefore such robust enzymes supply economically appealing materials.32,33 The isolation and comprehensively characterization of pure laccase from Bacillus sp. SL-1 revealed its high production yield and stability.27
Aldehyde dehydrogenase (ALDH; aldehyde: NAD(P)+oxidoreductase, EC 1.2.1.5) constitute a group of enzymes that catalyze the conversion of aldehydes to the corresponding acids mediated by an NAD(P)+-dependent virtually irreversible reaction making it potentially useful in an industrial settings. The ALDH is very unstable because of the spontaneous oxidation,34 therefore, there is considerable interest in production of stable ALDH, which can be used more efficiently in the pharmaceutical and fine chemicals industries for the production of aldehydes, ketones, and chiral alcohols. The production of chiral compounds is particularly desired because this is an increasingly important step in the synthesis of chirally pure pharmaceutical agents.35 On the other hand, the ALDH family is the most important detoxifying enzyme due to its role in the removal of the accumulated aldehyde metabolits.36 Many human diseases are associated with lack of ALDH enzymes and the increased level of aldehydes in the body contributes to the pathology of a variety of metabolic disorders. In this investigation, sequencing analysis of ycbD (SL-1) showed that this gene was composed of 1467 bp, corresponding to 488 amino acid residues with a molecular mass of 52,912 Da. The pairwise alignment of aldehyde dehydrogenase (SL-1) gene with DNA sequences of homologous enzymes from B. licheniformis (ATCC 14580) and B. subtilis 168 showed 100.0% and 74.23% identities, respectively.
Hydrolases (EC3)
Hydrolases catalyze hydrolysis using cleavage of substrates by water molecule. In biological systems, the reactions contain the cleavage of peptide bonds in proteins, glycosidic bonds in carbohydrates, and ester bonds in lipids. Generally, larger molecules are broken down to smaller fragments by hydrolases.25
The therapeutic enzyme L-asparaginase (EC 3.5.1.1; L-asparagine amidohydrolase) is an important antineoplastic agent primarily applied for management of acute lymphoblastic leukaemia (ALL). Eighty percentage of ALL type of leukemia affect children with only 20% of cases shown in adults.37 L-asparaginase catalyzes the conversion of l-asparagine to l-aspartic acid and ammonia. The antileukemic activity of L-asparaginase is due to depletion of the circulating L-asparagine concentration in the extracellular fluid and hence reduction of its availability for the tumor cells which lack asparagine synthetase required for L-asparagine intracellular synthesis. This leads to the inhibition of protein synthesis in tumor cells and induction of apoptosis. However, the normal cells are not affected significantly due to their intact system for asparagine biosynthesis.38 Currently, in the United States, three asparaginase formulations are widely used against ALL: native E. coli asparaginase, its pegylated form, and the product from cultures of Erwinia chrysanthemi.39 Despite significant advancement in production of therapeutical forms of L-asparaginase, development of anti-asparaginase antibody in the patients is responsible for its major toxicity and resistance in asparaginase therapy and also reduces the therapeutic efficacy in some cancer cases. Considering that the patients do not develop cross reactivity, when a patient shows hypersensitivity to one type of L-asparaginase, it can be replaced with the enzymes obtained from different bacterial sources.37 Pairwise alignment of ansA3 (SL-1) and ansA3 gene from B. licheniformis (strain ATCC 14580) showed 99.90% identity with just a single T522A silent substitution (Table 4). The sequence alignment of genes for L-asparaginase from Bacillus sp. SL-1 and that of B. subtilis 168 indicated 72.04% identity (Table 3). Recently L-asparaginase from B. licheniformis with low glutaminase activity has been considered as a key therapeutic agent in the treatment of ALL.40 Preliminary activity assay on recombinant L-asparaginase corresponding to ansA3 gene from Bacillus sp. SL-1in our lab showed that it is not functional. However, the gene for second homologous enzyme with asparaginase activity called ansA1 was also isolated from Bacillus sp. SL-1 with 99.07% similarity to ansA1 from B. licheniformis ATCC14580 (Table 4) and the corresponding recombinant protein was produced in high purity showing excellent enzymatic activity (unpublished data). Our findings are in contrast to the results reported by Sudhir et al where they showed that the enzyme encoded by ansA3 from B. licheniformis MTCC 429 is active, while the enzyme from ansA1is highly unstable.41
Allantoinases (pucH) are members of amidohydrolase superfamily, which are involved in purine metabolism and also catalyze the hydrolysis of a broad range of substrates containing amide or ester functional groups at carbon and phosphorus centers.42 Despite their importance in the purine catabolic pathway, sequences of microbial allantoinases with proven activity are scarce and only the enzymes from Escherichia coli has been studied in detail in this regard.43 It has been reported that allantoinase from B. licheniformis presents an inverted enantioselectivity towards allantoin (R-enantioselective) that is not observed for other allantoinases, which makes it an interesting candidate for biotechnological applications.42 The pucH(SL-1) sequence analysis from Bacillus sp. SL-1 showed 99.66 % similarity to B. licheniformis allantoinase gene with three nucleotide substitution (G397A, C850A and C896T) that led to three amino acid modifications in the corresponding protein sequence (Table 4).
Glutaminase (EC 3.5.1.2) is an oncolytic enzyme that catalyzes the deamination of L-glutamine to L-glutamic acid and ammonia with high specificity. L-glutaminase such as L-asparaginase is very significant anticancer enzyme in the treatment of acute lymphoblastic leukemia and other kinds of cancer through the L-glutamine amino acid depletion in cancerous cells.44,45 These enzymes (i.e. L-glutaminase and L-asparaginase) are commonly used of therapeutic agents accounting for about 40% of the total worldwide enzyme sales.45 Moreover, microbial glutaminases are enzymes with emerging potential in food industries.44 One of the potential application of recombinant B. licheniformis glutaminase is the bioconversion of glutamine to flavor-enhancing glutamic acid in fermented food products.46 There have been only a few reports on the characterization of recombinant glutaminases. The glsA(SL-1) from Bacillus sp. SL-1 with 99.70% similarity to glutaminase gene from B. licheniformis consists of 984 bp corresponding to 327 residues with A435G and A649T nucleotide substitutions leading to I145M and I217F residue changes in the protein sequence, respectively (Table 4).
A glutamate-specific endopeptidase (GSE) (EC 3.4.21.19) has the ability to cleave peptide bonds preceded by Glu and/or Asp residues. Its activity to Asp containing substrates contributes only 0.3% of that towards Glu substrates, demonstrating its high specificity for peptide bonds formed by α-carboxyl groups of Glu amino acids47 The GSE from B. licheniformis has been used to hydrolyze α-lactalbumin, and the hydrolysate formed nanotubes due to the specificity of GSE-BL. It has been suggested that these nanotubes can be used as drug carriers and viscosifying agents with the advantages that they are biocompatible and of low toxicity.48 Also, the biochemical properties of this type of enzyme are useful for its usage in protein structure analysis, solid phase peptide synthesis, and biochemistry industry.49 Sequencing results of blaSE (SL-1) showed 100.0% and 56.80% identity with B. licheniformis and B. subtilis, respectively.
Cellulose is the major component of plant biomass, which originally comes from solar energy through the process known as photosynthesis and is the most abundant renewable energy on Earth.50 Microorganisms produce multiple enzyme components to degrade cellulose, known as the cellulase (EC 3.2.1.4) system. The main application of these enzymes are in food and detergent industries.51 Microbial cellulase applications have been widely studied in pharmaceutical industries, mainly because of its huge economic potential in the conversion of plant biomass into ethanol and other chemicals. Recently, improved novel tubular cellulose (TC), a porous cellulosic material has been produced by enzymatic treatment with cellolase in order to prepare nanotubes, which have gained broad attention as major nanomedicine tools in drug targeting and delivery systems.52
Also, mannan polysaccharide is one of the main polymers in hemicellulose, a major component of lignocellulose. The mannan endo-1,4-β-mannosidase (EC 3.2.1.78), commonly named β-mannanase, is an enzyme that can catalyze random hydrolysis of β-1,4-mannosidic linkages in the main chain of mannans, glucomannans and galactomannans.53 This enzyme has several applications in many industries including food, feed, pharmaceutical, pulp/paper industries, and gas well stimulation and pretreatment of lignocellulosic biomass for the production of second generation biofuel.54 The application of mannan endo-1,4-β-mannosidase for the production of prebiotic mannan-oligosaccharides from byproducts of cheap agricultural sources has found increased interests.55 Additionally, the β-mannanase and mannosidase secreted from the microflora in colon environment can degrade the hydrogel-based therapeutics and release the drug molecule from a galactomannan-based hydrogel.56,57 The sequence analysis of bglC1 (SL-1) and gmuG (SL-1) genes of Bacillus sp. SL-1 showed 100.0% homology with both of these genes from B. licheniformis as well as 76.43% and 72.48% identities with those of B. subtilis 168, respectively.
Lyases (EC4)
Lyases add some groups to double bonds or form double bonds through the elimination of groups. Thus bonds are cleaved by a principle different from hydrolysis. These are often referred to as synthase enzymes which differ from other enzymes in that one substrate is required in the forward direction, whereas two substrates are needed for the backward reaction.26
Pectin is the most complex polysaccharides widely found in plant cell wall, consist of a backbone of D-galacturonic acid residues, which are partially methylesterified. Pectate lyase (EC 4.2.2.2) (pelA) cleaves the α-1,4 glycosidic bond of polygalacturonic acid (PGA) via a β- elimination reaction and generates a unsaturated bond at the non-reducing end of the newly formed oligogalacturonide.58 These enzymes are of great commercial value for various industrial applications such as improving juice yields and clarity in fruit juice industry.59 Genes encoding microbial pectate lyase have been identified from many microorganisms, including different Bacillus strains, and the corresponding enzymes form a superfamily based on their amino acid sequence similarity.60 The sequence alignment of pelA from Bacillus sp. SL-1 revealed 100.0% and 51.12% homology with DNA sequences of B. licheniformis (ATCC 14580) and B. subtilis 168 pectate lyase coding genes, respectively.
Isomerases (EC5)
Isomerases mediate the transferring of groups from one position to another one in the same molecule. On the other hands, these enzymes change the structure of a substrate by rearranging its atoms.25
L-arabinose isomerase (EC 5.3.1.4) catalyzes the reversible isomerization of L-arabinose to L-ribulose involved in either the pentose phosphate or the phosphoketolase pathway in carbohydrate metabolism.61 Isomerase enzymes play a crucial role in the synthesis of uncommon sugars, simply termed rare sugars. Due to their scarcity in the nature and uneconomical method of production, rare sugars are available only in limited amounts and at a high cost.62 D-Tagatose, a natural rare monosaccharide, is an isomer of D-galactose which can be manufactured by the chemical or enzymatic isomerization of D-galactose.63,64 Among the biocatalysts, L-arabinose isomerase has been mostly applied for D-tagatose production because of the industrial feasibility for the use of D-galactose as a substrate.64 D-Tagatose has attracted a great attention in recent years for its low caloric diet and can be used as sweetener in several foods, beverages, and dietary supplements. There are numerous reports indicates the useful medical properties of this sugar such as prebiotic, antioxidant and tooth-friendly as well as reduction of symptoms associated with type 2 diabetes, anemia, hemophilia and hyperglycemia.63,65
L-arabinose isomerase from various bacteria have been identified and studied from a number of microbial sources, but little information is available about this enzyme from B. licheniformis, and L- arabinose isomerase specific towards only L-arabinose.61 DNA sequence analysis of araA2 (SL-1) revealed an open reading frame of 1425 bp, capable of encoding a polypeptide of 474 amino acid residues with a calculated isoelectric point of pH 4.8 and a molecular mass of 53,500 Da. Based on analysis of the genome sequence, araA2 gene from Bacillus sp. SL-1 showed 100.0% and 57.52% identity with l- arabinose isomerase gene from B. licheniformis (ATCC 14580) and B. subtilis 168, respectively.
Conclusion
In the present study, halo-thermo tolerance Bacillus sp. SL1 isolate was evaluated for molecular characterization of its potential important pharmaceutical and industrial enzymes. Based on the sequence alignment results, 6 out of 10 studied enzymes from Bacillus sp. SL-1 showed 100.0% similarity at the nucleotide level to the corresponding genes of these enzymes in B. licheniformis (ATCC 14580) and demonstrated extensive organizational relationship between two strains. In the case of three studied enzymes (laccase, glutaminase, and allantoinase), their gene sequences showed more than 99% identity with B. licheniformis and the modifications in nucleotides translates to amino acid substitution in protein sequences. Asparaginase from Bacillus sp. SL1 was the only enzyme among others with just a single nucleotide silent substitution. Molecular characterizations of industrial enzyme sequences of newly isolated Bacillus sp. SL-1 provides useful information for comparative and evolutionary studies of different species within the industrial microorganisms including B. subtilis, B. licheniformis group. In the meantime, these studies may offer new information regarding the evolution and application of these closely related species. Since, the most industrial processes are often performed in harsh conditions like extreme pH, temperature, or ionic strength, therefore such robust enzymes provide economically appealing materials to be used under specific physicochemical situations.27,66 Thus, halo-thermo tolerance Bacillus sp. SL-1 could represent an excellent source of enzymes that can function at extreme conditions working as biocatalysts in medical, pharmaceutical, chemical and other industries.
Acknowledgments
This work was financially supported by Anatomical Sciences Research Center, Kashan University of Medical Science for providing the Postgraduate Research Grant scheme toward the PhD thesis of AS (grant no. 9171). The aid of Biotechnology Research Center, Tabriz University of Medical Sciences for providing all necessary research facilitates is highly appreciated.
Ethical Issues
Not applicable.
Conflict of Interest
The authors declare no conflict of interests.
References
- 1.Nigam PS. Microbial enzymes with special characteristics for biotechnological applications. Biomolecules. 2013;3(3):597–611. doi: 10.3390/biom3030597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Li S, Yang X, Yang S, Zhu M, Wang X. Technology prospecting on enzymes: Application, marketing and engineering. Comput Struct Biotechnol J. 2012;2:e201209017. doi: 10.5936/csbj.201209017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Polak J, Jarosz-Wilkolazka A, Szalapata K, Graz M, Osinska-Jaroszuk M. Laccase-mediated synthesis of a phenoxazine compound with antioxidative and dyeing properties--the optimisation process. N Biotechnol. 2016;33(2):255–62. doi: 10.1016/j.nbt.2015.09.004. [DOI] [PubMed] [Google Scholar]
- 4.Johnson EA. Biotechnology of non-saccharomyces yeasts-the ascomycetes. Appl Microbiol Biotechnol. 2013;97(2):503–17. doi: 10.1007/s00253-012-4497-y. [DOI] [PubMed] [Google Scholar]
- 5.Sanchez S, Demain AL. Enzymes and bioconversions of industrial, pharmaceutical, and biotechnological significance. Org Process Res Dev. 2010;15(1):224–30. doi: 10.1021/op100302x. [DOI] [Google Scholar]
- 6.Vellard M. The enzyme as drug: Application of enzymes as pharmaceuticals. Curr Opin Biotech. 2003;14(4):444–50. doi: 10.1016/S0958-1669(03)00092-2. [DOI] [PubMed] [Google Scholar]
- 7.Mane P, Tale V. Overview of microbial therapeutic enzymes. Int J Curr Microbiol App Sci. 2015;4(4):17–26. [Google Scholar]
- 8.Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001;7(11):3314–24. [PubMed] [Google Scholar]
- 9.Silverman RB, Holladay MW. The organic chemistry of drug design and drug action: 3rd ed. 3rd ed. USA: Academic press; 2014. [Google Scholar]
- 10.Ferguson MJ, Ahmed FY, Cassidy J. The role of pro-drug therapy in the treatment of cancer. Drug Resist Updat. 2001;4(4):225–32. doi: 10.1054/drup.2001.0207. [DOI] [PubMed] [Google Scholar]
- 11.Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T. et al. Prodrugs: Design and clinical applications. Nat Rev Drug Discov. 2008;7(3):255–70. doi: 10.1038/nrd2468. [DOI] [PubMed] [Google Scholar]
- 12.Wu KM. A new classification of prodrugs: Regulatory perspectives. Pharmaceuticals. 2009;2(3):77–81. doi: 10.3390/ph2030077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mikolasch A, Hildebrandt O, Schluter R, Hammer E, Witt S, Lindequist U. Targeted synthesis of novel beta-lactam antibiotics by laccase-catalyzed reaction of aromatic substrates selected by pre-testing for their antimicrobial and cytotoxic activity. Appl Microbiol Biotechnol. 2016;100(11):4885–99. doi: 10.1007/s00253-016-7288-z. [DOI] [PubMed] [Google Scholar]
- 14.Sharma R, Chisti Y, Banerjee UC. Production, purification, characterization, and applications of lipases. Biotechnol Adv. 2001;19(8):627–62. doi: 10.1016/s0734-9750(01)00086-6. [DOI] [PubMed] [Google Scholar]
- 15.Adrio JL, Demain AL. Microbial enzymes: Tools for biotechnological processes. Biomolecules. 2014;4(1):117–39. doi: 10.3390/biom4010117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kirk O, Borchert TV, Fuglsang CC. Industrial enzyme applications. Curr Opin Biotechnol. 2002;13(4):345–51. doi: 10.1016/s0958-1669(02)00328-2. [DOI] [PubMed] [Google Scholar]
- 17.Ran N, Zhao L, Chen Z, Tao J. Recent applications of biocatalysis in developing green chemistry for chemical synthesis at the industrial scale. Green Chem. 2008;10(4):361–72. doi: 10.1039/B716045C. [DOI] [Google Scholar]
- 18. Adrio JL, Demain AL. Microbial Cells and Enzymes A Century of Progress. In: Barredo JL, editor. Microbial enzymes and biotransformations. USA: Humana Press; 2005.
- 19.Sarmiento F, Peralta R, Blamey JM. Cold and hot extremozymes: Industrial relevance and current trends. Front Bioeng Biotechnol. 2015;3:148. doi: 10.3389/fbioe.2015.00148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Safary A, Moniri R, Mirhashemi SM, Nikzad H, Khiavi MA. Phylogenetic and biochemical characterization of a new halo-thermotolerant, biofilm-forming bacillus from saline lake of iran. Pol J Microbiol. 2013;62(4):419–25. [PubMed] [Google Scholar]
- 21.Klibanov AM. Improving enzymes by using them in organic solvents. Nature. 2001;409(6817):241–6. doi: 10.1038/35051719. [DOI] [PubMed] [Google Scholar]
- 22.Rey MW, Ramaiya P, Nelson BA, Brody-Karpin SD, Zaretsky EJ, Tang M. et al. Complete genome sequence of the industrial bacterium bacillus licheniformis and comparisons with closely related bacillus species. Genome Biol. 2004;5(10):R77. doi: 10.1186/gb-2004-5-10-r77. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Veith B, Herzberg C, Steckel S, Feesche J, Maurer KH, Ehrenreich P. et al. The complete genome sequence of bacillus licheniformis dsm13, an organism with great industrial potential. J Mol Microbiol Biotechnol. 2004;7(4):204–11. doi: 10.1159/000079829. [DOI] [PubMed] [Google Scholar]
- 24.Thompson JD, Higgins DG, Gibson TJ. Clustal w: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673–80. doi: 10.1093/nar/22.22.4673. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Gurung N, Ray S, Bose S, Rai V. A broader view: Microbial enzymes and their relevance in industries, medicine, and beyond. Biomed Res Int. 2013;2013:329121. doi: 10.1155/2013/329121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Vasudevan DM, Sreekumari S, Vaidyanathan K. Textbook of biochemistry for medical students. 6th ed. New Delhi, India: Jaypee Brothers Medical Publishers (P) Ltd; 2011. [Google Scholar]
- 27.Safary A, Moniri R, Hamzeh-Mivehroud M, Dastmalchi S. A strategy for soluble overexpression and biochemical characterization of halo-thermotolerant bacillus laccase in modified e. Coli. J Biotechnol. 2016;227:56–63. doi: 10.1016/j.jbiotec.2016.04.006. [DOI] [PubMed] [Google Scholar]
- 28.Mikolasch A, Niedermeyer TH, Lalk M, Witt S, Seefeldt S, Hammer E. et al. Novel penicillins synthesized by biotransformation using laccase from trametes spec. Chem Pharm Bull (Tokyo) 2006;54(5):632–8. doi: 10.1248/cpb.54.632. [DOI] [PubMed] [Google Scholar]
- 29.Mikolasch A, Niedermeyer TH, Lalk M, Witt S, Seefeldt S, Hammer E. et al. Novel cephalosporins synthesized by amination of 2,5-dihydroxybenzoic acid derivatives using fungal laccases ii. Chem Pharm Bull (Tokyo) 2007;55(3):412–6. doi: 10.1248/cpb.55.412. [DOI] [PubMed] [Google Scholar]
- 30.Mikolasch A, Wurster M, Lalk M, Witt S, Seefeldt S, Hammer E. et al. Novel beta-lactam antibiotics synthesized by amination of catechols using fungal laccase. Chem Pharm Bull (Tokyo) 2008;56(7):902–7. doi: 10.1248/cpb.56.902. [DOI] [PubMed] [Google Scholar]
- 31.Kunamneni A, Camarero S, Garcia-Burgos C, Plou FJ, Ballesteros A, Alcalde M. Engineering and applications of fungal laccases for organic synthesis. Microb Cell Fact. 2008;7:32. doi: 10.1186/1475-2859-7-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Santhanam N, Vivanco JM, Decker SR, Reardon KF. Expression of industrially relevant laccases: Prokaryotic style. Trends Biotechnol. 2011;29(10):480–9. doi: 10.1016/j.tibtech.2011.04.005. [DOI] [PubMed] [Google Scholar]
- 33.Brander S, Mikkelsen JD, Kepp KP. Characterization of an alkali- and halide-resistant laccase expressed in e. Coli: Cota from bacillus clausii. PLoS One. 2014;9(6):e99402. doi: 10.1371/journal.pone.0099402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Lo HF, Chen YJ. Gene cloning and biochemical characterization of a nad(p)+ -dependent aldehyde dehydrogenase from bacillus licheniformis. Mol Biotechnol. 2010;46(2):157–67. doi: 10.1007/s12033-010-9290-5. [DOI] [PubMed] [Google Scholar]
- 35.Machielsen R, Uria AR, Kengen SW, van der Oost J. Production and characterization of a thermostable alcohol dehydrogenase that belongs to the aldo-keto reductase superfamily. Appl Environ Microbiol. 2006;72(1):233–8. doi: 10.1128/AEM.72.1.233-238.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Chen CH, Ferreira JC, Gross ER, Mochly-Rosen D. Targeting aldehyde dehydrogenase 2: New therapeutic opportunities. Physiol Rev. 2014;94(1):1–34. doi: 10.1152/physrev.00017.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Zuo S, Xue D, Zhang T, Jiang B, Mu W. Biochemical characterization of an extremely thermostable l-asparaginase from thermococcus gammatolerans EJ3. J Mol Catal B Enzym. 2014;109:122–9. doi: 10.1016/j.molcatb.2014.08.021. [DOI] [Google Scholar]
- 38.Kotzia GA, Labrou NE. L-asparaginase from erwinia chrysanthemi 3937: Cloning, expression and characterization. J Biotechnol. 2007;127(4):657–69. doi: 10.1016/j.jbiotec.2006.07.037. [DOI] [PubMed] [Google Scholar]
- 39.Jia M, Xu M, He B, Rao Z. Cloning, expression, and characterization of l-asparaginase from a newly isolated bacillus subtilis b11-06. J Agric Food Chem. 2013;61(39):9428–34. doi: 10.1021/jf402636w. [DOI] [PubMed] [Google Scholar]
- 40.Mahajan RV, Kumar V, Rajendran V, Saran S, Ghosh PC, Saxena RK. Purification and characterization of a novel and robust l-asparaginase having low-glutaminase activity from bacillus licheniformis: In vitro evaluation of anti-cancerous properties. PLoS One. 2014;9(6):e99037. doi: 10.1371/journal.pone.0099037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Sudhir AP, Dave BR, Prajapati AS, Panchal K, Patel D, Subramanian RB. Characterization of a recombinant glutaminase-free l-asparaginase (ansa3) enzyme with high catalytic activity from bacillus licheniformis. Appl Biochem Biotechnol. 2014;174(7):2504–15. doi: 10.1007/s12010-014-1200-z. [DOI] [PubMed] [Google Scholar]
- 42.Conejero-Muriel M, Martinez-Gomez AI, Martinez-Rodriguez S, Gavira JA. Cloning, expression, purification, crystallization and preliminary x-ray characterization of allantoinase from bacillus licheniformis atcc 14580. Acta Crystallogr F Struct Biol Commun. 2014;70(Pt 11):1513–6. doi: 10.1107/S2053230X14021608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Martinez-Gomez AI, Soriano-Maldonado P, Andujar-Sanchez M, Clemente-Jimenez JM, Rodriguez-Vico F, Neira JL. et al. Biochemical and mutational studies of allantoinase from bacillus licheniformis cect 20t. Biochimie. 2014;99:178–88. doi: 10.1016/j.biochi.2013.12.002. [DOI] [PubMed] [Google Scholar]
- 44.Nandakumar R, Yoshimune K, Wakayama M, Moriguchi M. Microbial glutaminase: Biochemistry, molecular approaches and applications in the food industry. J Mol Catal B Enzym. 2003;23(2):87–100. doi: 10.1016/S1381-1177(03)00075-4. [DOI] [Google Scholar]
- 45.El-Ghonemy DH. Microbial amidases and their industrial applications: A review. J Med Microbiol Diagn. 2015;4(1):1. [Google Scholar]
- 46.Sinsuwan S, Yongsawatdigul J, Chumseng S, Yamabhai M. Efficient expression and purification of recombinant glutaminase from bacillus licheniformis (glsa) in escherichia coli. Protein Expr Purif. 2012;83(1):52–8. doi: 10.1016/j.pep.2012.03.001. [DOI] [PubMed] [Google Scholar]
- 47.Wehofsky N, Wissmann J, Alisch M, Bordusa F. Engineering of substrate mimetics as novel-type substrates for glutamic acid-specific endopeptidases: Design, synthesis, and application. Biochim Biophys Acta. 2000;1479(1-2):114–22. doi: 10.1016/s0167-4838(00)00016-9. [DOI] [PubMed] [Google Scholar]
- 48.Ye W, Wang H, Ma Y, Luo X, Zhang W, Wang J. et al. Characterization of the glutamate-specific endopeptidase from bacillus licheniformis expressed in escherichia coli. J Biotechnol. 2013;168(1):40–5. doi: 10.1016/j.jbiotec.2013.08.009. [DOI] [PubMed] [Google Scholar]
- 49.Ye W, Liu J, Wang H, Wang J, Wang X. Cloning, expression, purification, and characterization of a glutamate-specific endopeptidase from bacillus licheniformis. Protein Expr Purif. 2012;82(1):138–43. doi: 10.1016/j.pep.2011.12.001. [DOI] [PubMed] [Google Scholar]
- 50.Liu Y, Zhang J, Liu Q, Zhang C, Ma Q. Molecular cloning of novel cellulase genes cel9a and cel12a from bacillus licheniformis gxn151 and synergism of their encoded polypeptides. Curr Microbiol. 2004;49(4):234–8. doi: 10.1007/s00284-004-4291-x. [DOI] [PubMed] [Google Scholar]
- 51.Maeda RN, Barcelos CA, Santa Anna LM, Pereira N, Jr. Cellulase production by penicillium funiculosum and its application in the hydrolysis of sugar cane bagasse for second generation ethanol production by fed batch operation. J Biotechnol. 2013;163(1):38–44. doi: 10.1016/j.jbiotec.2012.10.014. [DOI] [PubMed] [Google Scholar]
- 52.Koutinas A, Papafotopoulou-Patrinou E, Gialleli AI, Petsi T, Bekatorou A, Kanellaki M. Production of nanotubes in delignified porous cellulosic materials after hydrolysis with cellulase. Bioresour Technol. 2016;213:169–71. doi: 10.1016/j.biortech.2016.03.065. [DOI] [PubMed] [Google Scholar]
- 53.Songsiriritthigul C, Buranabanyat B, Haltrich D, Yamabhai M. Efficient recombinant expression and secretion of a thermostable gh26 mannan endo-1,4-beta-mannosidase from bacillus licheniformis in escherichia coli. Microb Cell Fact. 2010;9:20. doi: 10.1186/1475-2859-9-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Gubitz G, Sachslehner A, Haltrich D. Microbial mannanases: Substrates, production, and applications. In: Himmel ME, Baker JO, Saddler JN, editors. Glycosyl Hydrolases for Biomass Conversion. Washington: American Chemical Society; 2001.
- 55.Biggs P, Parsons CM. The effects of several oligosaccharides on true amino acid digestibility and true metabolizable energy in cecectomized and conventional roosters. Poult Sci. 2007;86(6):1161–5. doi: 10.1093/ps/86.6.1161. [DOI] [PubMed] [Google Scholar]
- 56.Burke MD, Park JO, Srinivasarao M, Khan SA. A novel enzymatic technique for limiting drug mobility in a hydrogel matrix. J Control Release. 2005;104(1):141–53. doi: 10.1016/j.jconrel.2005.01.017. [DOI] [PubMed] [Google Scholar]
- 57.Dionisio M, Grenha A. Locust bean gum: Exploring its potential for biopharmaceutical applications. J Pharm Bioallied Sci. 2012;4(3):175–85. doi: 10.4103/0975-7406.99013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Vierhuis E, Korver M, Schols HA, Voragen AG. Structural characteristics of pectic polysaccharides from olive fruit (olea europaea cv moraiolo) in relation to processing for oil extraction. Carbohyd Polym. 2003;51(2):135–48. doi: 10.1016/S0144-8617(02)00158-3. [DOI] [Google Scholar]
- 59.Berensmeier S, Singh SA, Meens J, Buchholz K. Cloning of the pela gene from bacillus licheniformis 14a and biochemical characterization of recombinant, thermostable, high-alkaline pectate lyase. Appl Microbiol Biotechnol. 2004;64(4):560–7. doi: 10.1007/s00253-003-1446-9. [DOI] [PubMed] [Google Scholar]
- 60.Hatada Y, Kobayashi T, Ito S. Enzymatic properties of the highly thermophilic and alkaline pectate lyase pel-4b from alkaliphilic bacillus sp. Strain p-4-n and the entire nucleotide and amino acid sequences. Extremophiles. 2001;5(2):127–33. doi: 10.1007/s007920100182. [DOI] [PubMed] [Google Scholar]
- 61.Prabhu P, Tiwari MK, Jeya M, Gunasekaran P, Kim IW, Lee JK. Cloning and characterization of a novel l-arabinose isomerase from bacillus licheniformis. Appl Microbiol Biotechnol. 2008;81(2):283–90. doi: 10.1007/s00253-008-1652-6. [DOI] [PubMed] [Google Scholar]
- 62.Izumori K. Bioproduction strategies for rare hexose sugars. Naturwissenschaften. 2002;89(3):120–4. doi: 10.1007/s00114-002-0297-z. [DOI] [PubMed] [Google Scholar]
- 63.Wanarska M, Kur J. A method for the production of d-tagatose using a recombinant pichia pastoris strain secreting beta-d-galactosidase from arthrobacter chlorophenolicus and a recombinant l-arabinose isomerase from arthrobacter sp. 22c. Microb Cell Fact. 2012;11:113. doi: 10.1186/1475-2859-11-113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Oh DK. Tagatose: Properties, applications, and biotechnological processes. Appl Microbiol Biotechnol. 2007;76(1):1–8. doi: 10.1007/s00253-007-0981-1. [DOI] [PubMed] [Google Scholar]
- 65.Jung ES, Kim HJ, Oh DK. Tagatose production by immobilized recombinant escherichia coli cells containing geobacillus stearothermophilus l-arabinose isomerase mutant in a packed-bed bioreactor. Biotechnol Prog. 2005;21(4):1335–40. doi: 10.1021/bp050078p. [DOI] [PubMed] [Google Scholar]
- 66.Gomes J, Steiner W. The biocatalytic potential of extremophiles and extremozymes. Food Technol Biotechnol. 2004;42(4):223–35. [Google Scholar]
